SCHEMBL3595246

SCHEMBL3595246

CNC(=O)c1cc(Nc2cc(NC(=O)c3ccc(F)c(C(F)(F)F)c3)ccc2C)n(-c2cc(NN3CCN(C)CC3)ncn2)n1

nearest known ligand 0.51

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
BRAF P15056 15/20 0.51
MAPK14 Q16539 1/20 0.44
LYN P07948 3/20 0.43
ABL1 P00519 2/20 0.43
BCR P11274 1/20 0.43
INSR P06213 2/20 0.43
LCK P06239 2/20 0.43
SRC P12931 2/20 0.43
KDR P35968 2/20 0.43
HCK P08631 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13503065 0.89 MAPK14 (0.44) BRAFMAPK14LYNABL1BCR
SCHEMBL3577470 0.88 BRAF (0.58) BRAFLYNINSRLCKSRC
SCHEMBL3020423 0.87 BRAF (0.52) BRAFMAPK14LYNABL1BCR
SCHEMBL3593315 0.86 BRAF (0.53) BRAFMAPK14LYNINSRLCK
SCHEMBL14218737 0.86 MAPK14 (0.47) BRAFMAPK14LYNINSRLCK
SCHEMBL3587169 0.85 MAPK14 (0.42) BRAFMAPK14LYNABL1INSR
SCHEMBL3589374 0.85 BRAF (0.55) BRAFMAPK14LYNINSRLCK
SCHEMBL3587714 0.85 MAPK14 (0.50) BRAFMAPK14LYNINSRLCK
SCHEMBL3596814 0.85 BRAF (0.51) BRAFMAPK14LYNINSRLCK
SCHEMBL3578499 0.84 BRAF (0.49) BRAFLYNINSRLCKSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202876-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2012-06-19 US claimed
US-20100029605-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-02-04 US claimed
EP-2057146-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-05-13 EP claimed
WO-2008042639-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-04-10 WO claimed
US-8202876-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2012-06-19 US disclosed
US-8202876-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2012-06-19 US disclosed
US-8202876-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2012-06-19 US disclosed
US-20100029605-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-02-04 US disclosed
EP-2057146-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-05-13 EP disclosed
WO-2008042639-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029605-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS FYN, ABL2, LCK BRAF 11/4885MAPK14 337/4885LYN 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.